La cadena de opciones muestra datos clave de las opciones de acciones de Energy Vault Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Energy Vault Holdings..

Energy Vault Holdings (NYSE:NRGV) Bolsa, Cadena de Opciones

Energy Vault Holdings

Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.

Energy Vault Holdings Inc

WIIM

HOLX

HOLX stock has given up its prior gain. Hologic shares were trading higher after Morgan Stanley and UBS raised their respective price targets on the stock.

Raymond James analyst Melissa Fairbanks reiterates Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and raises the price target from $720 to $875.

News

Price Target

Reiteration

Analyst Ratings

MPWR

Raymond James Reiterates Outperform on Monolithic Power Systems, Raises Price Target to $875

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Shrenik Kothari downgraded the rating for CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from Outperform to Neutral and maintained the price target of $460. CyberArk Software shares closed at $411.47 on Thursday. <a href="https://www.benzinga.com/quote/cybr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Lizzie Dove downgraded Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) from Neutral to Sell and raised the price target from $87 to $105. Avis Budget shares closed at $170.24 on Thursday. <a href="https://www.benzinga.com/quote/car/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Michael Ciarmoli downgraded Albany International Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) from Buy to Hold and slashed the price target from $70 to $55. Albany International shares closed at $54.19 on Thursday. <a href="https://www.benzinga.com/quote/ain/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David Manthey downgraded Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) from Outperform to Neutral and cut the price target from $145 to $130. Builders FirstSource shares closed at $127.13 on Thursday. <a href="https://www.benzinga.com/quote/BLDR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Aaron Kimson downgraded Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) from Market Outperform to Market Perform and maintained the price target of $95. Procore Technologies shares closed at $71.63 on Thursday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYBR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CYBR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png" alt="" class="wp-image-1010876" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Trading Ideas

BLDR

CYBR

PCOR

This CyberArk Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Raymond James analyst Frank Louthan maintains Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) with a Outperform and raises the price target from $4.5 to $5.

LUMN

Raymond James Maintains Outperform on Lumen Technologies, Raises Price Target to $5

Raymond James analyst Srini Pajjuri reiterates KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Outperform and raises the price target from $850 to $950.

KLAC

Raymond James Reiterates Outperform on KLA, Raises Price Target to $950

Barclays analyst Brandt Montour maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Overweight and raises the price target from $25 to $31.

NCLH

Barclays Maintains Overweight on Norwegian Cruise Line, Raises Price Target to $31

Wedbush analyst Alicia Reese maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and raises the price target from $142 to $165.

RBLX

Wedbush Maintains Outperform on Roblox, Raises Price Target to $165

On Friday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.57</a>.
The&nbsp;company reported sales&nbsp;of $3.68 billion, up 4% year over year, beating the <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785919/regeneron-pharmaceuticals-likely-to-report-lower-q2-earnings-these-most-accura" rel="noreferrer noopener">consensus of $3.29 billion</a>.
In the second quarter, U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;decreased 25% year-over-year to $1.15&nbsp;billion, including $393 million from Eylea HD and $754 million from Eylea.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Net product sales of Eylea HD increased in the second quarter of 2025, compared to the second quarter of 2024, due to higher sales volumes driven by increased demand.
Net product sales of EYLEA were negatively impacted by lower sales volumes due to continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, continued transition of patients to EYLEA HD, and a lower net selling price.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased, due to the company&#8217;s share of profits from the commercialization of antibodies, which were $1.282 billion and $988&nbsp;million in the second quarter of 2025 and 2024, respectively.
The change in the company&#8217;s share of profits from the commercialization of antibodies was driven by higher profits associated with an increase in Dupixent sales.
<h2 class="wp-block-heading">Pipeline Update</h2>
In its earnings press release, Regeneron said it expects regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration (FDA) applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for macular edema following retinal vein occlusion), which have <a target="_blank" href="https://www.benzinga.com/pressreleases/25/08/g46788448/regeneron-reports-second-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">PDUFA dates in August 2025</a>.
The anticipated delay concerns observations from an FDA general site inspection at the filler for EYLEA HD in these regulatory applications, Catalent Indiana LLC, recently acquired by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
The inspection was completed in mid-July and was not specific to EYLEA HD. Novo has communicated with the FDA and expects to submit its response next week.
Based on the company&#8217;s review of the observations, Novo&#8217;s proposed response to the FDA, and the progress the company has made with alternate third-party fillers, the company anticipates an expeditious resolution of the filling issues for EYLEA HD.
The FDA issued a Complete Response Letter (CRL) for the application for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent site inspection.
<h2 class="wp-block-heading">Outlook</h2>
Regeneron expects a 2025 GAAP gross margin of approximately 83%, compared to the <a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">prior guidance of 83%–84%</a>.
The company expects an adjusted gross margin of approximately 86%, compared to the&nbsp;prior guidance of 86%–87%.
Price Action:&nbsp;REGN stock is trading higher by 3.77% to $566 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46789863/amazon-post-earnings-decline-totally-wrong-says-analyst-as-ceo-points-out-aws-has-more-demand-than-we-have-capacity" target="_blank" rel="noreferrer noopener">Amazon Post-Earnings Decline &#8216;Totally Wrong,&#8217; Says Analyst As CEO Points Out AWS Has &#8216;More Demand Than We Have Capacity&#8217;</a></li>
</ul>
Photo by Marianne Campolongo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

REGN

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

Barclays analyst Ross Sandler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $640 to $810.

Barclays Maintains Overweight on Meta Platforms, Raises Price Target to $810

Raymond James analyst Srini Pajjuir reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $230 to $240.

AAPL

Raymond James Reiterates Outperform on Apple, Raises Price Target to $240

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $180 to $225.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $225

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and raises the price target from $77 to $78.

Barclays Maintains Overweight on Masco, Raises Price Target to $78

Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $52 to $50.

APLS

Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50

<ul>
<li>UNH</li>
<li>AMZN</li>
<li>FIG</li>
<li>GLD</li>
<li>NVDA</li>
<li>RDDT</li>
<li>AAPL</li>
<li>TSLA</li>
<li>AMD</li>
<li>META</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AMZN

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of Aug. 1, 2025 (Via Swaggy Stocks)

Barclays analyst Benjamin Budish maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Overweight and raises the price target from $460 to $463.

LPLA

Barclays Maintains Overweight on LPL Finl Hldgs, Raises Price Target to $463

MCVT

Mill City Ventures Establishes $500M Equity Line Agreement With Alliance Global Partners To Advance SUI Treasury Strategy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler analyst Brent Bracelin upgraded the rating for AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) from Neutral to Overweight and raised the price target from $240 to $350. AppFolio shares closed at $267.38 on Thursday. <a href="https://www.benzinga.com/quote/appf/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Ken Newman upgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Sector Weight to Overweight and announced a $50 price target. Cognex shares closed at $40.77 on Thursday. <a href="https://www.benzinga.com/quote/cgnx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Noah Zatzkin upgraded the rating for THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) from Underweight to Sector Weight. Thor Industries shares closed at $90.99 on Thursday. <a href="https://www.benzinga.com/quote/tho/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow upgraded Canada Goose Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#TSX">GOOS</a>) from Equal-Weight to Overweight and raised the price target from C$19 to C$20. <a href="https://www.benzinga.com/quote/goos/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying APPF stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/APPF/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-1024x557.png" alt="" class="wp-image-1010863" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Upgrades

APPF

CGNX

GOOS

TSX:GOOS

This AppFolio Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

JMP Securities analyst Andrew Boone reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and maintains $285 price target.

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $285 Price Target

Raymond James analyst Martin Auster reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $370 to $424.

ALNY

Raymond James Reiterates Outperform on Alnylam Pharmaceuticals, Raises Price Target to $424

Hudson Global, Inc. (the "Company" or "Hudson RPO") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>), a leading global total talent solutions company, announced today the strategic integration of McKinsey CMO Group ("CMRG"), a boutique firm specializing in recruitment marketing, brand strategy, and talent engagement.
The addition of CMRG's expertise will enable Hudson RPO to further support clients in building stronger employer brands, elevating candidate experiences, and attracting top-tier talent in today's competitive hiring environment. Together, Hudson RPO and CMRG will offer a more holistic suite of services, blending best-in-class recruitment operations with cutting-edge employer branding and engagement strategies.
As part of the integration, Crystal McKinsey, Founder &amp; CEO of CMRG, will join Hudson RPO as the Global Head of Marketing. In this role, she will lead the Company's global marketing efforts and enhance Hudson RPO's capabilities in talent attraction, employer branding, and candidate engagement.

HSON

Hudson RPO Integrates McKinsey CMO Group To Strengthen Employer Branding And Talent Engagement

Press Releases

Energy Vault Holdings, Inc. Receives Notice of Continued Listing Standards From NYSE

Energy Vault Holdings, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

Energy Vault Schedules Conference Call to Discuss First Quarter 2025 Financial Results

Energy Vault Reports First Quarter 2025 Financial Results

Energy Vault, Jupiter Power Announce Agreement for Additional 100 MW/200 MWh Battery Energy Storage System

Energy Vault Achieves Major Strategic Milestone with Commercial Operation of Cross Trails BESS, Marking the First Asset Placed in Service Under "Own & Operate" Growth Strategy

Comments

Energy Vault Holdings

Energy Vault Holdings (NRGV) Opciones

Energy Vault Holdings (NYSE:NRGV) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL